Systemic therapy for bone metastases

Cancer Control

Volumn 19, Issue 2, 2012, Pages 145-153

  Loftus, Loretta S ^a,b   Edwards Bennett, Sophia ^a,b   Sokol, Gerald H ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DASATINIB; DENOSUMAB; IBANDRONIC ACID; ODANACATIB; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

BLADDER CANCER; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER SURVIVAL; CELLULITIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENDOCARDITIS; ERYSIPELAS; GASTROINTESTINAL IRRITATION; HEALTH CARE UTILIZATION; HUMAN; HYPERCALCEMIA; HYPERMAGNESEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; HYPOPHOSPHATEMIA; INFECTIOUS ARTHRITIS; JAW OSTEONECROSIS; KIDNEY CANCER; LUNG CANCER; MULTIPLE MYELOMA; MYALGIA; NEPHROTOXICITY; NONHUMAN; OVERALL SURVIVAL; PANCREATITIS; PATHOLOGIC FRACTURE; PRACTICE GUIDELINE; PROSTATE CANCER; REVIEW; RISK REDUCTION; STOMACH IRRITATION; SYSTEMIC THERAPY; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

EID: 84859460363     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201900209     Document Type: Review

References (80)

1. Lipton A. Bone loss prevention in cancer: new developments and perspectives. Semin Oncol. 2010;37(suppl 1):S1-S2.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165-176.
3. Harvey HA, Cream LR. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007;7(suppl 1):S7-S13.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Natl Rev Cancer. 2002;2(8):584-593.
5. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
6. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12(20 pt 2):6305S-6308S.
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2):165-176.
8. Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110(8):1860-1867.
9. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879-882.
10. Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593-602.
11. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12): 2613-2621.
12. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082-1090.
13. Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002;4(1):30-34.
14. Green J, Clézardin P. The molecular basis of bisphosphonate activity: a preclinical perspective. Semin Oncol. 2010;37(suppl 1):S3-S11.
15. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004; 9(suppl 4):3-13.
16. Rosen L, Harland SJ, Oosterlinck W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol. 2002;25(6 suppl 1):S19-S24.
17. Fornier MN. Denosumab: second chapter in controlling bone metastases or a new book? J Clin Oncol. 2010;28(35):5127-5131.
18. Mortimer JE, Pal SK. Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol. 2010;37(suppl 1):S66-S72.
19. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008;26(30):4875-4882.
20. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;3:CD003474.
21. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
22. Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter comparative trial. Cancer. 2003;98(8):1735-1744.
23. Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36-43.
24. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28(35):5132-5139.
25. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastases. Int J Cancer. 2009;125(7):1705-1709.
26. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
27. Saad F, Eastham J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology. 2010;76(5):1175-1181.
28. Saad F, Eastham J. Maintaining bone health in prostate cancer throughout the disease continuum. Semin Oncol. 2010;37(suppl 1):S30-S37.
29. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-822.
30. Saad F, Eastham JA. Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer. Semin Oncol. 2010;37(suppl 1):S38-S44.
31. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int. 2005;96(7):964-969.
32. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98(5):962-969.
33. Kijima T, Fujii Y, Suyama T, et al. Radiotherapy to bone metastases from renal cell carcinoma with or without zoledronate. BJU Int. 2009;103(5):620-624.
34. Mulders PFA, Miller K, Tchekmedyian NS, et al. Long-term reduction in risk of skeletal complications with zoledronic acid in patients with advanced renal cell carcinoma or bladder cancer. Presented at the 22nd Annual European Association of Urology Congress; March 21-24, 2007; Berlin, Germany. Abstract No. 971.
35. Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15(4):382-389.
36. Berenson JR. Therapeutic options in the management of myeloma bone disease. Semin Oncol. 2010;37(suppl 1):S20-S29.
37. Terpos E, Berenson J, Cook RJ, et al. Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease. Leukemia. 2010;24(5):1043-1049.
38. Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340(8827):1049-1052.
39. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488-493.
40. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind comparative trial. Cancer J. 2001;7(5):377-387.
41. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001; 19(2):558-567.
42. Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11(8):539-547.
43. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol. 2010;37(suppl 1):S53-S65.
44. Gallo M, De Luca A, Lamura L, et al. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer. Ann Oncol. 2012;23(3): 597-604.
45. Chlebowski RT, Chen Z, Cauley JA, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28(22):3582-3590.
46. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010;28(22):3577-3581.
47. Rennert G, Pinchev M, Rennert HS, et al. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011;29(9):1146-1150.
48. Ha TC, Li H. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96(12):1796-1801.
49. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009: 360(7):679-691.
50. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12(7):631-641.
51. Coleman R, Bundred N, De Boer R, et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Poster presented at 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, Texas.
52. Monsees GM, Malone KE, Tang MT, et al. Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst. 2011;103(23):1752-1760.
53. Coleman RE, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011;365(15):1396-1405.
54. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(1):89-90.
55. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010;341:c4444.
56. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304(6):657-663.
57. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360(17):1789-1792.
58. Lowes R. FDA studying link between bisphosphonates, esophageal cancer. Medscape News Today. July 21, 2001. http://www.medscape.com/viewarticle/746793. Accessed December 22, 2011.
59. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22): 4925-4935.
60. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008;113(1):193-201.
61. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27(10):1564-1571.
62. Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18(6):1378-1391.
63. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29(9):1221-1227.
64. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. v.2.2011:MS37-MS39. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
65. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. v.4.2011:MS22-MS23. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
66. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: kidney cancer. v.2.2011:MS11-MS12. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehensive Cancer Network, Inc; 2011. Accessed February 3, 2012.
67. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. v.1.2012:MS24-MS25. Available at: http://www.nccn.org. Fort Washington, PA: National Comprehen sive Cancer Network, Inc; 2011. Accessed February 3, 2012.
68. Delea TE, McKiernan J, Brandman J, et al. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. J Thorac Oncol. 2006;1(6):571-576.
69. Delea T, Langer C, McKiernan J, et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology. 2004;67(5-6):390-396.
70. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal- related events in patients with prostate cancer. Am J Manag Care. 2008;14(5):317-322.
71. Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol. 2006;4(7):341-347.
72. Gryta T. Amgen's Xgeva gets FDA approval in cancer-related bone complications. The Wall Street Journal. Health Section, November 18, 2010. Available at: http://online.wsj.com/article/SB10001424052748704410404575623530026654838.html. Accessed February 3, 2012.
73. West H. Denosumab for prevention of skeletal-related events in patients with bone metastases from solid tumors: incremental benefit, debatable value. J Clin Oncol. 2011;29(9):1095-1098.
74. Saad F, Lipton A. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev. 2010;36(2):177-184.
75. Araujo J, Logothetis C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 2010;36(6): 492-500.
76. Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10(6):452-458.
77. Huang EH, Singh B, Cristofanilli M, et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res. 2009;155(2):231-236.
78. Baselga J, Rothenberg ML, Tabernero J, et al. TGF-beta signalingrelated markers in cancer patients with bone metastasis. Biomarkers. 2008;13(2):217-236.
79. Duivenvoorden WC, Hirte HW, Singh G. Transforming growth factor beta 1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis. 1999;17(1):27-34.
80. Staflin K, Krueger JS, Hachmann J, et al. Targeting activated integrin alphavbeta3 with patient-derived antibodies impacts late-stage multiorgan metastasis. Clin Exp Metastasis. 2010;27(4):217-231.